What is Icu Medical's earnings per share (EPS)?

Icu Medical (ICUI) reported diluted earnings per share of $0.03 for fiscal year 2025. This represents a 100.6% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Icu Medical Financials

ICUI

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows Icu Medical (ICUI) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 19 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 38/100

Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

Icu Medical has an operating margin of 1.9%, meaning the company retains $2 of operating profit per $100 of revenue. This below-average margin results in a low score of 26/100, suggesting thin profitability after operating expenses. This is up from 1.8% the prior year.

Growth

Icu Medical's revenue declined 6.3% year-over-year, from $2.4B to $2.2B. This contraction results in a growth score of 23/100.

Leverage

Icu Medical carries a low D/E ratio of 0.60, meaning only $0.60 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 90/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

Icu Medical's current ratio of 2.39 indicates adequate short-term liquidity, earning a score of 44/100. The company can meet its near-term obligations, though with limited headroom.

Cash Flow

Icu Medical has a free cash flow margin of 4.1%, earning a moderate score of 35/100. The company generates positive cash flow after capital investments, but with room for improvement.

Returns

Icu Medical generates a 0.0% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 11/100. This is up from -6.0% the prior year.

Altman Z-Score Grey Zone

2.02

Icu Medical scores 2.02, placing it in the grey zone between 1.81 and 2.99. This signals moderate financial risk that warrants monitoring.

Piotroski F-Score Neutral

6/9

Icu Medical passes 6 of 9 financial strength tests. All 4 profitability signals pass (positive income, cash flow, and earnings quality), 1 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.

Earnings Quality Cash-Backed

245.69x

For every $1 of reported earnings, Icu Medical generates $245.69 in operating cash flow ($179.8M OCF vs $732K net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Interest Coverage At Risk

0.5x

Icu Medical earns $0.5 in operating income for every $1 of interest expense ($42.8M vs $93.3M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$2.2B

YoY-6.3%

5Y CAGR+11.9%

10Y CAGR+20.6%

Icu Medical generated $2.2B in revenue in fiscal year 2025. This represents a decrease of 6.3% from the prior year.

EBITDA

$243.6M

YoY-7.2%

5Y CAGR+5.8%

10Y CAGR+10.9%

Icu Medical's EBITDA was $243.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 7.2% from the prior year.

Net Income

$732K

YoY+100.6%

5Y CAGR-61.5%

10Y CAGR-33.8%

Icu Medical reported $732K in net income in fiscal year 2025. This represents an increase of 100.6% from the prior year.

EPS (Diluted)

$0.03

YoY+100.6%

5Y CAGR-62.5%

10Y CAGR-36.3%

Icu Medical earned $0.03 per diluted share (EPS) in fiscal year 2025. This represents an increase of 100.6% from the prior year.

Cash & Balance Sheet

Free Cash Flow

$91.8M

YoY-26.4%

5Y CAGR-6.8%

10Y CAGR+6.0%

Icu Medical generated $91.8M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 26.4% from the prior year.

Cash & Debt

$308.0M

YoY-0.2%

5Y CAGR-4.9%

10Y CAGR-0.9%

Icu Medical held $308.0M in cash against $1.3B in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

25M

YoY+0.7%

5Y CAGR+3.2%

10Y CAGR+4.4%

Icu Medical had 25M shares outstanding in fiscal year 2025. This represents an increase of 0.7% from the prior year.

Margins & Returns

Gross Margin

36.8%

YoY+2.2pp

5Y CAGR+0.5pp

10Y CAGR-16.1pp

Icu Medical's gross margin was 36.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 2.2 percentage points from the prior year.

Operating Margin

1.9%

YoY+0.1pp

5Y CAGR-5.8pp

10Y CAGR-18.1pp

Icu Medical's operating margin was 1.9% in fiscal year 2025, reflecting core business profitability. This is up 0.1 percentage points from the prior year.

Net Margin

0.0%

YoY+5.0pp

5Y CAGR-6.8pp

10Y CAGR-13.1pp

Icu Medical's net profit margin was 0.0% in fiscal year 2025, showing the share of revenue converted to profit. This is up 5.0 percentage points from the prior year.

Return on Equity

0.0%

YoY+6.0pp

5Y CAGR-5.8pp

10Y CAGR-7.7pp

Icu Medical's ROE was 0.0% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 6.0 percentage points from the prior year.

Capital Allocation

R&D Spending

$87.5M

YoY-1.3%

5Y CAGR+15.3%

10Y CAGR+18.7%

Icu Medical invested $87.5M in research and development in fiscal year 2025. This represents a decrease of 1.3% from the prior year.

Share Buybacks

$8.8M

YoY-26.9%

5Y CAGR-7.4%

10Y CAGR+19.1%

Icu Medical spent $8.8M on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding. This represents a decrease of 26.9% from the prior year.

Capital Expenditures

$88.0M

YoY+10.9%

5Y CAGR-0.9%

10Y CAGR+21.1%

Icu Medical invested $88.0M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 10.9% from the prior year.

ICUI Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$2.2B-6.3%	$2.4B+5.4%	$2.3B-0.9%	$2.3B+73.2%	$1.3B+3.6%	$1.3B
Cost of Revenue	$1.4B-9.5%	$1.6B+2.5%	$1.5B-4.0%	$1.6B+91.8%	$824.8M+1.9%	$809.5M
Gross Profit	$822.0M-0.3%	$824.8M+11.5%	$739.9M+6.0%	$697.8M+42.0%	$491.5M+6.5%	$461.5M
R&D Expenses	$87.5M-1.3%	$88.6M+3.8%	$85.3M-8.2%	$93.0M+95.8%	$47.5M+10.6%	$42.9M
SG&A Expenses	$625.2M-2.1%	$638.8M+5.3%	$606.7M-0.3%	$608.3M+101.1%	$302.6M+6.6%	$284.0M
Operating Income	$42.8M-0.3%	$43.0M+88.2%	$22.8M+153.2%	-$42.9M-134.8%	$123.2M+25.6%	$98.2M
Interest Expense	$93.3M-12.4%	$106.5M+3.7%	$102.7M+45.1%	$70.8M+8152.3%	$858K-51.1%	$1.8M
Income Tax	$2.4M-95.3%	$51.7M+206.2%	-$48.6M-21.2%	-$40.1M-300.1%	$20.1M+88.7%	$10.6M
Net Income	$732K+100.6%	-$117.7M-296.9%	-$29.7M+60.1%	-$74.3M-172.0%	$103.1M+18.7%	$86.9M
EPS (Diluted)	$0.03+100.6%	$-4.83-292.7%	$-1.23+60.5%	$-3.11-165.6%	$4.74+17.9%	$4.02

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	$540.7M+0.7%	$537.0M-2.2%	$548.9M-9.2%	$604.7M-4.0%	$629.8M+6.9%	$589.1M-1.2%	$596.5M+5.3%	$566.7M
Cost of Revenue	$337.7M+0.5%	$336.1M-1.4%	$340.8M-13.6%	$394.6M-2.0%	$402.5M+4.8%	$384.3M-1.2%	$389.0M+2.0%	$381.4M
Gross Profit	$203.0M+1.0%	$200.9M-3.5%	$208.1M-1.0%	$210.1M-7.5%	$227.3M+10.9%	$204.9M-1.2%	$207.4M+12.0%	$185.2M
R&D Expenses	$21.1M-0.8%	$21.3M-2.8%	$21.9M-6.1%	$23.3M+4.2%	$22.4M+6.3%	$21.0M-10.1%	$23.4M+7.1%	$21.8M
SG&A Expenses	$155.8M+2.0%	$152.8M-4.2%	$159.4M+1.4%	$157.2M-1.0%	$158.8M-2.4%	$162.7M+2.0%	$159.5M+1.2%	$157.7M
Operating Income	$5.6M-58.9%	$13.7M+29.6%	$10.6M-17.9%	$12.9M-65.8%	$37.7M+357.6%	$8.2M+7.1%	$7.7M+172.2%	-$10.7M
Interest Expense	$30.9M+56.3%	$19.8M-3.6%	$20.5M-6.7%	$22.0M-35.7%	$34.2M+38.7%	$24.7M+3.5%	$23.8M+0.3%	$23.8M
Income Tax	-$2.7M-303.2%	-$658K-155.9%	$1.2M-74.2%	$4.6M-85.7%	$32.0M+112.9%	$15.1M+703.8%	$1.9M-30.7%	$2.7M
Net Income	-$15.7M-363.3%	-$3.4M-109.6%	$35.3M+328.3%	-$15.5M+35.1%	-$23.8M+27.8%	-$33.0M-54.1%	-$21.4M+45.8%	-$39.5M
EPS (Diluted)	N/A	$-0.14-109.8%	$1.43+327.0%	$-0.63	N/A	$-1.35-53.4%	$-0.88+46.0%	$-1.63

ICUI Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$4.1B-3.6%	$4.2B-4.0%	$4.4B-3.0%	$4.5B+140.1%	$1.9B+6.6%	$1.8B
Current Assets	$1.2B-17.4%	$1.4B+18.1%	$1.2B-1.1%	$1.2B+19.9%	$1.0B+11.8%	$920.8M
Cash & Equivalents	$308.0M-0.2%	$308.6M+21.4%	$254.2M+21.8%	$208.8M-62.2%	$552.8M+39.6%	$396.1M
Inventory	$615.9M+5.3%	$584.7M-17.6%	$709.4M+1.9%	$696.0M+139.8%	$290.2M-7.8%	$314.9M
Accounts Receivable	$180.5M-1.3%	$182.8M+13.2%	$161.6M-27.1%	$221.7M+109.4%	$105.9M-14.7%	$124.1M
Goodwill	$1.5B+4.7%	$1.4B-2.7%	$1.5B+1.6%	$1.4B+3236.3%	$43.4M+31.6%	$33.0M
Total Liabilities	$1.9B-13.9%	$2.2B-0.7%	$2.3B-7.0%	$2.4B+816.4%	$264.7M+1.3%	$261.4M
Current Liabilities	$498.9M-10.3%	$556.2M+15.4%	$481.8M-2.6%	$494.6M+146.3%	$200.8M+2.7%	$195.5M
Long-Term Debt	$1.3B-17.4%	$1.5B-2.9%	$1.6B-2.8%	$1.6B	$0	N/A
Total Equity	$2.1B+8.1%	$2.0B-7.4%	$2.1B+1.6%	$2.1B+29.3%	$1.6B+7.6%	$1.5B
Retained Earnings	$690.9M+0.1%	$690.2M-14.6%	$807.8M-3.5%	$837.5M-8.1%	$911.8M+12.8%	$808.7M

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$4.1B-1.3%	$4.1B-0.1%	$4.1B-1.8%	$4.2B-0.5%	$4.2B-2.3%	$4.3B+0.4%	$4.3B0.0%	$4.3B
Current Assets	$1.2B-1.4%	$1.2B+2.3%	$1.2B-17.1%	$1.4B-1.3%	$1.4B+14.6%	$1.3B+1.8%	$1.2B+4.1%	$1.2B
Cash & Equivalents	$308.0M+2.7%	$299.7M-0.1%	$300.0M+3.6%	$289.7M-6.1%	$308.6M-1.3%	$312.5M+3.3%	$302.6M+20.4%	$251.4M
Inventory	$615.9M-1.1%	$622.4M+1.0%	$616.5M+4.4%	$590.3M+1.0%	$584.7M-15.5%	$692.0M+1.3%	$682.9M-1.5%	$693.0M
Accounts Receivable	$180.5M-5.8%	$191.5M+6.7%	$179.5M+5.0%	$170.9M-6.5%	$182.8M+5.1%	$174.0M+14.6%	$151.8M+4.5%	$145.2M
Goodwill	$1.5B+0.1%	$1.5B-0.2%	$1.5B+3.2%	$1.5B+1.6%	$1.4B-3.1%	$1.5B+1.9%	$1.5B-0.6%	$1.5B
Total Liabilities	$1.9B-2.5%	$2.0B-0.8%	$2.0B-9.3%	$2.2B-1.9%	$2.2B-0.8%	$2.3B+0.3%	$2.2B+1.3%	$2.2B
Current Liabilities	$498.9M+1.2%	$492.9M+2.1%	$482.8M-12.1%	$549.0M-1.3%	$556.2M+1.2%	$549.6M+7.4%	$511.9M+12.4%	$455.4M
Long-Term Debt	$1.3B-3.7%	$1.3B-1.8%	$1.3B-10.1%	$1.5B-2.8%	$1.5B-0.7%	$1.5B-0.7%	$1.6B-0.7%	$1.6B
Total Equity	$2.1B-0.2%	$2.1B+0.5%	$2.1B+6.4%	$2.0B+1.1%	$2.0B-4.1%	$2.0B+0.5%	$2.0B-1.5%	$2.1B
Retained Earnings	$690.9M-2.2%	$706.6M-0.5%	$710.0M+5.2%	$674.7M-2.2%	$690.2M-3.3%	$714.0M-4.4%	$747.0M-2.8%	$768.4M

ICUI Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	$179.8M-11.9%	$204.0M+22.8%	$166.2M+367.5%	-$62.1M-123.2%	$267.5M+20.1%	$222.8M
Capital Expenditures	$88.0M+10.9%	$79.4M-5.4%	$83.9M-7.1%	$90.3M+31.8%	$68.5M-25.5%	$92.0M
Free Cash Flow	$91.8M-26.4%	$124.7M+51.5%	$82.3M+154.0%	-$152.4M-176.6%	$199.0M+52.2%	$130.7M
Investing Cash Flow	$122.2M+237.4%	-$89.0M-1.2%	-$87.9M+95.4%	-$1.9B-2005.6%	-$90.7M+7.6%	-$98.1M
Financing Cash Flow	-$311.5M-458.3%	-$55.8M-55.1%	-$36.0M-102.2%	$1.6B+9803.8%	-$16.9M-42075.0%	-$40K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	$8.8M-26.9%	$12.0M+28.3%	$9.3M-14.1%	$10.9M+30.6%	$8.3M-35.3%	$12.9M

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	$60.6M+6.9%	$56.7M+405.8%	$11.2M-78.2%	$51.3M+27.7%	$40.2M+11.3%	$36.1M-56.0%	$82.0M+79.0%	$45.8M
Capital Expenditures	$24.6M-15.2%	$29.1M+47.6%	$19.7M+34.7%	$14.6M-39.3%	$24.1M+20.9%	$19.9M+2.3%	$19.5M+22.3%	$15.9M
Free Cash Flow	$36.0M+30.1%	$27.6M+425.6%	-$8.5M-123.1%	$36.7M+127.8%	$16.1M-0.5%	$16.2M-74.1%	$62.5M+109.2%	$29.9M
Investing Cash Flow	-$18.4M+38.8%	-$30.0M-116.0%	$187.5M+1215.1%	-$16.8M+36.7%	-$26.5M-16.1%	-$22.9M-5.4%	-$21.7M-21.4%	-$17.9M
Financing Cash Flow	-$34.5M-34.2%	-$25.7M+86.8%	-$195.0M-246.2%	-$56.3M-587.8%	-$8.2M+21.1%	-$10.4M0.0%	-$10.4M+61.3%	-$26.8M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

ICUI Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	36.8%+2.2pp	34.6%+1.9pp	32.8%+2.2pp	30.6%-6.7pp	37.3%+1.0pp	36.3%
Operating Margin	1.9%+0.1pp	1.8%+0.8pp	1.0%+2.9pp	-1.9%-11.2pp	9.4%+1.6pp	7.7%
Net Margin	0.0%+5.0pp	-4.9%-3.6pp	-1.3%+1.9pp	-3.3%-11.1pp	7.8%+1.0pp	6.8%
Return on Equity	0.0%+6.0pp	-6.0%-4.6pp	-1.4%+2.1pp	-3.5%-9.9pp	6.4%+0.6pp	5.8%
Return on Assets	0.0%+2.8pp	-2.8%-2.1pp	-0.7%+1.0pp	-1.7%-7.1pp	5.5%+0.6pp	4.9%
Current Ratio	2.39-0.2	2.59+0.1	2.53+0.0	2.50-2.6	5.13+0.4	4.71
Debt-to-Equity	0.60-0.2	0.78+0.0	0.74-0.0	0.78+0.8	0.00-0.2	0.17
FCF Margin	4.1%-1.1pp	5.2%+1.6pp	3.6%+10.3pp	-6.7%-21.8pp	15.1%+4.8pp	10.3%

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	37.5%+0.1pp	37.4%-0.5pp	37.9%+3.2pp	34.8%-1.3pp	36.1%+1.3pp	34.8%0.0pp	34.8%+2.1pp	32.7%
Operating Margin	1.0%-1.5pp	2.5%+0.6pp	1.9%-0.2pp	2.1%-3.9pp	6.0%+4.6pp	1.4%+0.1pp	1.3%+3.2pp	-1.9%
Net Margin	-2.9%-2.3pp	-0.6%-7.1pp	6.4%+9.0pp	-2.6%+1.2pp	-3.8%+1.8pp	-5.6%-2.0pp	-3.6%+3.4pp	-7.0%
Return on Equity	-0.7%-0.6pp	-0.2%-1.8pp	1.7%+2.5pp	-0.8%+0.4pp	-1.2%+0.4pp	-1.6%-0.6pp	-1.1%+0.9pp	-1.9%
Return on Assets	-0.4%-0.3pp	-0.1%-0.9pp	0.9%+1.2pp	-0.4%+0.2pp	-0.6%+0.2pp	-0.8%-0.3pp	-0.5%+0.4pp	-0.9%
Current Ratio	2.39-0.1	2.450.0	2.44-0.1	2.590.0	2.59+0.3	2.29-0.1	2.41-0.2	2.61
Debt-to-Equity	0.60-0.0	0.62-0.0	0.63-0.1	0.75-0.0	0.78+0.0	0.750.0	0.760.0	0.76
FCF Margin	6.7%+1.5pp	5.1%+6.7pp	-1.6%-7.6pp	6.1%+3.5pp	2.6%-0.2pp	2.8%-7.7pp	10.5%+5.2pp	5.3%

Similar Companies

Warby Parker Inc WRBY

$2.6B

Envista Holdings Corp NVST

$4.2B

Dentsply Sirona Inc XRAY

$2.3B

Merit Med Sys Inc MMSI

$4.1B

Teleflex Inc TFX

$5.3B

Frequently Asked Questions

What is Icu Medical's annual revenue?

Icu Medical (ICUI) reported $2.2B in total revenue for fiscal year 2025. This represents a -6.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Icu Medical's revenue growing?

Icu Medical (ICUI) revenue declined by 6.3% year-over-year, from $2.4B to $2.2B in fiscal year 2025.

Is Icu Medical profitable?

Yes, Icu Medical (ICUI) reported a net income of $732K in fiscal year 2025, with a net profit margin of 0.0%.

What is Icu Medical's EBITDA?

Icu Medical (ICUI) had EBITDA of $243.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Icu Medical have?

As of fiscal year 2025, Icu Medical (ICUI) had $308.0M in cash and equivalents against $1.3B in long-term debt.

What is Icu Medical's gross margin?

Icu Medical (ICUI) had a gross margin of 36.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Icu Medical's operating margin?

Icu Medical (ICUI) had an operating margin of 1.9% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Icu Medical's net profit margin?

Icu Medical (ICUI) had a net profit margin of 0.0% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Icu Medical's return on equity (ROE)?

Icu Medical (ICUI) has a return on equity of 0.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Icu Medical's free cash flow?

Icu Medical (ICUI) generated $91.8M in free cash flow during fiscal year 2025. This represents a -26.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Icu Medical's operating cash flow?

Icu Medical (ICUI) generated $179.8M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Icu Medical's total assets?

Icu Medical (ICUI) had $4.1B in total assets as of fiscal year 2025, including both current and long-term assets.

What are Icu Medical's capital expenditures?

Icu Medical (ICUI) invested $88.0M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Icu Medical spend on research and development?

Icu Medical (ICUI) invested $87.5M in research and development during fiscal year 2025.

Does Icu Medical buy back shares?

Yes, Icu Medical (ICUI) spent $8.8M on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

How many shares does Icu Medical have outstanding?

Icu Medical (ICUI) had 25M shares outstanding as of fiscal year 2025.

What is Icu Medical's current ratio?

Icu Medical (ICUI) had a current ratio of 2.39 as of fiscal year 2025, which is generally considered healthy.

What is Icu Medical's debt-to-equity ratio?

Icu Medical (ICUI) had a debt-to-equity ratio of 0.60 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Icu Medical's return on assets (ROA)?

Icu Medical (ICUI) had a return on assets of 0.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Icu Medical's Altman Z-Score?

Icu Medical (ICUI) has an Altman Z-Score of 2.02, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios—working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets—to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Icu Medical's Piotroski F-Score?

Icu Medical (ICUI) has a Piotroski F-Score of 6 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Icu Medical's earnings high quality?

Icu Medical (ICUI) has an earnings quality ratio of 245.69x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Icu Medical cover its interest payments?

Icu Medical (ICUI) has an interest coverage ratio of 0.5x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Icu Medical?

Icu Medical (ICUI) scores 38 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.